How Can a Patent Be Enforced in Canada (2026): Injunctions, Damages, PM(NOC) & PTA Timelines

Understanding how can a patent be enforced is the single most consequential question a Canadian patentee faces once infringement is suspected. As of June 2026, two regulatory developments have materially reshaped enforcement strategy: CIPO’s March 24, 2026 Practice Notice on patentable subject-matter, which resets the framework for validity challenges during litigation and prosecution, and Canada’s Patent Term Adjustment (PTA) regime, in force since January 1, 2025, which can extend a patent’s enforceable life. This guide delivers a practical, step-by-step enforcement playbook, covering injunctions, damages, the PM(NOC) linkage system for pharmaceutical patents, and the new PTA timelines, designed for in-house counsel, patent holders, and external litigators preparing an enforcement campaign in Canada.

Key takeaways at a glance:

• Primary route. Patent infringement in Canada is enforced through civil litigation in the Federal Court (nationwide jurisdiction) or a provincial superior court, not by CIPO or any administrative agency.
• Available remedies. Injunctions (interlocutory and permanent), compensatory damages or an accounting of profits, delivery up or destruction of infringing goods, and costs.
• PM(NOC) for pharma. Innovator patentees can invoke the Patented Medicines (Notice of Compliance) Regulations to delay generic market entry, a parallel enforcement track with its own timelines.
• PTA enforcement window. Patents eligible for PTA may receive additional days of term, directly extending the window for seeking damages and injunctive relief.
• Subject-matter risk. CIPO’s March 2026 Practice Notice increases the tactical importance of subject-matter invalidity arguments in both prosecution and litigation.

How to Enforce a Patent in Canada: Practical Step-by-Step Process

Enforcing a patent in Canada follows a logical sequence. Skipping steps, particularly evidence preservation, can undermine even the strongest infringement case. The process outlined below reflects current Federal Court practice and the Canada Patent Act framework.

Step 1, Confirm and Document Your Rights

Search the patent register Canada (the CIPO Canadian Patent Database) to confirm that the patent is in force, that all maintenance fees have been paid, and that you are the registered owner or exclusive licensee with standing to sue. Obtain certified copies of the patent and any assignments. If PTA has been granted, verify the adjusted expiry date, as this determines the remaining enforcement window.

Step 2, Preserve Evidence of Infringement

Collect and preserve evidence before alerting the infringer. This includes purchasing the suspected infringing product, downloading marketing materials, preserving web pages with archival tools, and retaining expert analysis confirming that the product or process falls within the patent claims. In urgent cases, consider seeking an Anton Piller order (a civil search order) from the Federal Court, though Canadian courts grant these sparingly and require strong evidence of a real risk that evidence will be destroyed.

Step 3, Send a Demand Letter

A well-drafted demand letter serves multiple purposes: it puts the infringer on notice (which can affect the damages analysis and availability of punitive remedies), it opens the door to negotiation, and it creates a documented record of the patentee’s diligence. The letter should identify the patent, the infringing product or process, and the remedies sought. Exercise caution with the language: overly aggressive threats can, in some circumstances, generate unjustified-threats counterclaims.

Step 4, Evaluate ADR vs. Litigation

Mediation, arbitration, and structured settlement discussions can resolve patent disputes faster and more cheaply than full Federal Court trials, which typically take two to four years to reach judgment. Industry observers note that many Canadian patent disputes, particularly in technology sectors, settle after the pleadings stage or following an interlocutory injunction ruling. Consider whether an early licensing arrangement achieves the commercial objective more efficiently than litigation.

Step 5, File the Infringement Action

If ADR is not viable, commence proceedings in the Federal Court of Canada (for nationwide relief) or a provincial superior court (for locally bounded claims). The Federal Court is the predominant venue for patent infringement Canada actions because it can grant nationwide injunctions and has specialized case-management judges familiar with intellectual property disputes. File a Statement of Claim, request case management, and consider whether to bring an immediate interlocutory injunction motion.

Who Enforces Patents and Where to Sue

A common misconception is that CIPO, the Canadian Intellectual Property Office, can enforce a patent. It cannot. CIPO administers the patent register, examines applications, and grants patents, but it has no enforcement jurisdiction. The question of who enforces a patent is answered entirely by private rights: the patent holder (or exclusive licensee) must bring a civil action in court.

Under the Canada Patent Act, the Federal Court has concurrent jurisdiction with provincial superior courts over patent infringement actions. In practice, the Federal Court handles the vast majority of cases because it offers nationwide remedies, experienced IP judges, and established procedural rules for patent litigation. Standing to sue belongs to the patentee and, where the licence so provides, to an exclusive licensee, though a non-exclusive licensee generally cannot bring an action without joining the patentee.

How Can a Patent Holder Seek an Injunction in Canada

A patent holder can seek an injunction, either interlocutory (pre-trial) or permanent (post-trial), and this remedy is often the most commercially valuable form of relief. An injunction halts the infringing activity entirely, which in many cases matters more to the patentee than monetary damages alone.

Interlocutory Injunction: The Three-Part Test

Canadian courts apply the well-established three-part test when deciding whether a patent holder can obtain an interlocutory injunction:

• Serious issue to be tried. The patentee must show that the infringement claim is not frivolous or vexatious. This is generally a low threshold.
• Irreparable harm. The patentee must demonstrate that it will suffer harm that cannot be adequately compensated by damages. In pharmaceutical and life-sciences cases, irreparable harm is often argued on the basis of lost market share, price erosion, or the difficulty of unwinding generic market penetration once it occurs.
• Balance of convenience. The court weighs the relative harm to each party. If the patentee will lose its entire market exclusivity without an injunction, and the defendant can be adequately compensated by an undertaking in damages, the balance typically favours the patentee.

Industry observers note that Federal Court trends between 2023 and 2026 reflect a heightened judicial focus on the irreparable-harm element, with courts demanding more concrete evidence, such as detailed market-impact affidavits and economic expert reports, rather than accepting general assertions of competitive harm.

Permanent Injunction

After trial, the court has broad discretion to grant a permanent injunction under the Patent Act. A successful patentee will usually obtain one, but the remedy remains discretionary. Courts may decline a permanent injunction where, for example, the patent is near expiry, the infringer has ceased the infringing activity, or the public interest weighs against it.

Extraordinary Pre-Trial Remedies

Beyond interlocutory injunctions, patentees may seek Anton Piller orders (civil search and seizure) and Mareva injunctions (asset-freezing orders). Both are exceptional remedies granted only where there is clear evidence of a risk that the defendant will destroy evidence or dissipate assets. Canadian courts apply these cautiously, and they are comparatively rare in patent litigation.

Practical Evidence Checklist for Injunction Motions

• Expert affidavit on claim construction and infringement analysis
• Market-impact report quantifying irreparable harm (lost sales, price erosion, loss of exclusivity)
• Evidence of the patent’s validity and prosecution history
• Undertaking as to damages (the patentee’s commitment to compensate the defendant if the injunction is later found to have been wrongly granted)
• Affidavit evidence on the defendant’s ability to satisfy a damages award if the injunction is refused

What Are the Possible Remedies for Patent Infringement

The Canada Patent Act provides several heads of relief once infringement is established. The patentee must elect between compensatory damages and an accounting of profits, the two remedies are mutually exclusive.

Compensatory Damages

Compensatory damages aim to put the patentee in the financial position it would have occupied had the infringement not occurred. There are two primary methods of calculation:

• Lost profits. If the patentee can show that it would have made the sales captured by the infringer, damages are calculated based on the profits the patentee would have earned. This requires evidence of manufacturing capacity, market demand, and the absence of non-infringing alternatives.
• Reasonable royalty. Where lost profits cannot be established, the court awards a reasonable royalty, the amount a willing licensee would have paid a willing licensor in a hypothetical arm’s-length negotiation.

Accounting of Profits

As an alternative to damages, the patentee may elect an accounting of profits, which requires the infringer to disgorge the profits attributable to the infringement. The key advantage is that it targets the infringer’s gains rather than the patentee’s losses, which can be beneficial where the infringer has earned substantial profits in a market the patentee does not directly serve. The assessment requires careful allocation of the infringer’s revenues and costs to the infringing activity.

Delivery Up, Punitive Damages, and Costs

Courts may also order delivery up or destruction of infringing products and tooling. Punitive damages in patent cases are exceptionally rare in Canada and are typically reserved for cases involving egregious or deliberate misconduct. Costs, a partial contribution toward the winning party’s legal fees, are awarded as a matter of course, though full indemnity costs remain unusual.

PM(NOC) Regime: Enforcing Pharmaceutical Patents in Canada

For pharmaceutical patent holders, the Patented Medicines (Notice of Compliance) Regulations, commonly known as PM(NOC), provide a specialized enforcement mechanism that operates alongside standard infringement litigation. Understanding how this regime works is essential for any innovator company seeking to protect market exclusivity for a patented drug in Canada.

How the Linkage System Works

Under the PM(NOC) regime, an innovator lists eligible patents on the Patent Register maintained by Health Canada. When a generic manufacturer files an abbreviated new drug submission (ANDS) seeking a Notice of Compliance (market authorization), it must either accept that the listed patents are valid and infringed (and wait for expiry) or serve a Notice of Allegation (NOA) asserting that the patents are invalid or not infringed. Once an NOA is served, the innovator may commence an action in the Federal Court within the prescribed timeframe. The commencement of such an action triggers a statutory stay that prevents Health Canada from issuing a Notice of Compliance to the generic for up to 24 months, unless the court orders otherwise.

Strategic Considerations Post-2017

The PM(NOC) regime was substantially amended effective September 21, 2017, shifting from a prohibition-application model to a full-action model in the Federal Court. Under the current framework, the patentee commences a standard patent infringement action, and the generic may counterclaim for a declaration of invalidity or non-infringement. Health Canada’s guidance on these regulations clarifies the procedural requirements and timelines. The likely practical effect of the 2017 amendments is that PM(NOC) proceedings now function more like regular patent litigation, with full discovery, expert evidence, and trial, industry observers note that this has increased both the cost and the strategic significance of early case assessment for both innovators and generics.

Coordinating PM(NOC) with Standard Infringement Actions

Innovators must carefully coordinate their PM(NOC) action with any independent infringement suit. The two proceedings may involve overlapping patents and issues but are procedurally distinct. Failing to commence the PM(NOC) action within the prescribed period results in the loss of the statutory stay, a potentially devastating outcome for market exclusivity.

Patent Term Adjustment (PTA): Why It Matters for Enforcement Windows

Canada’s Patent Term Adjustment regime, which came into force on January 1, 2025, allows patentees to recover additional days of patent term lost due to unreasonable delays by CIPO during prosecution. For enforcement purposes, PTA directly extends the window during which a patentee can seek injunctive relief and damages, making it a critical consideration in any enforcement strategy formulated after that date.

Eligibility and Filing Requirements

PTA is available for patents with a filing date on or after December 1, 2020. Patentees must file a request for PTA within the prescribed period after the patent is granted. The adjustment compensates for delays attributable to the patent office that exceed the legislated threshold, delays caused by the applicant are excluded from the calculation.

Key Legislative and Regulatory Timeline

PTA and Damages Calculations

Where a patent’s term has been extended via PTA, the additional period of exclusivity must be factored into any damages assessment. Early indications suggest that PTA-extended terms will become a focal point in settlement negotiations, as they increase the total economic value of the patent and the corresponding exposure for the infringer. Patentees should verify their PTA status before commencing any enforcement action.

How to Defend Against Patent Infringement: Practical Defences and Strategy

Defendants facing patent infringement claims in Canada have a robust set of defences. Understanding how to defend against patent infringement early in proceedings is critical, as the strongest defences often require prompt evidence collection and expert engagement.

Invalidity

The most powerful defence is to attack the validity of the patent itself. Common invalidity grounds include:

• Anticipation. The claimed invention was disclosed in prior art before the claim date.
• Obviousness. The invention would have been obvious to a person skilled in the art at the relevant date.
• Patentable subject-matter. The claimed invention does not fall within the categories of patentable subject-matter under the Canada Patent Act. CIPO’s March 24, 2026 Practice Notice has renewed attention on this ground, particularly for claims directed at software, business methods, medical diagnostic methods, and certain biotechnology inventions. Defendants should assess whether the patent claims at issue are vulnerable to a subject-matter challenge under the updated framework.
• Insufficient disclosure. The patent specification does not describe the invention in sufficient detail to enable a person skilled in the art to practise it.

Non-Infringement

A defendant may argue that its product or process does not fall within the scope of the patent claims, properly construed. Claim construction is a question of law determined by the court, and it is often the decisive issue in patent litigation. Where the claims are ambiguous, the doctrine of purposive construction, which considers the purpose and context of the claims rather than a purely literal reading, may work in either party’s favour.

Prior User Rights and Experimental Use

Under the Patent Act, a person who, before the claim date, was already using or making serious preparations to use the invention has a limited prior-user defence. The experimental-use exception permits bona fide research and experimentation directed at the patented invention without constituting infringement, though its scope in Canada remains narrower than in some other jurisdictions.

Tactical Considerations

Defendants should consider filing a counterclaim for invalidity early in proceedings, this puts the patentee on the back foot and may affect settlement dynamics. Early engagement of technical and economic experts is essential, particularly for anticipation and obviousness attacks where prior-art searches must be thorough and well-documented.

Costs, Security for Costs, and Practical Litigation Economics

Patent litigation in Canada is expensive. A full Federal Court trial typically costs each side between CAD 1 million and CAD 5 million, depending on complexity, the number of patents at issue, and the volume of discovery. Costs awards in Canada are partial, the winning party usually recovers only a fraction of its actual legal fees. The court may order security for costs where the plaintiff is a foreign entity or has limited assets in Canada, requiring the plaintiff to deposit funds or provide a bond before the action proceeds.

Staged enforcement, pursuing an interlocutory injunction before committing to a full trial, can serve as both a pressure tactic and a cost-management strategy, as a successful injunction motion often forces an early settlement.

Quick Reference Checklists and Timelines

Patentee Enforcement Checklist

1. Confirm patent is in force on the CIPO patent register; check PTA status and adjusted expiry date.
2. Collect and preserve evidence of infringement (products, marketing, web archives, expert reports).
3. Assess PM(NOC) applicability if the patent covers a pharmaceutical product.
4. Send demand letter with clear identification of the patent and infringing activity.
5. Evaluate ADR vs. litigation; obtain litigation budget estimates.
6. File Statement of Claim in Federal Court; request case management.
7. Consider interlocutory injunction motion (prepare evidence of irreparable harm).
8. Proceed through discovery, expert reports, and trial (or settle).
9. If successful, elect damages or accounting of profits and seek permanent injunction.

Defendant Response Checklist

1. Preserve all internal documents related to design, development, and commercialization of the accused product.
2. Retain patent litigation counsel and a technical expert immediately upon receipt of a demand letter or claim.
3. Conduct a prior-art search and assess invalidity defences (anticipation, obviousness, subject-matter).
4. Analyse claim construction, determine whether the accused product or process falls within the claims.
5. Consider filing a counterclaim for invalidity and a motion to strike weak claims.
6. Evaluate insurance coverage and exposure for damages or an accounting of profits.
7. Assess whether early settlement or licensing is commercially preferable to a full defence.

Key deadline callouts: For PM(NOC), the innovator must commence its action within the prescribed period after receiving the NOA or lose the statutory stay. For PTA, the request must be filed within the prescribed period after grant. Missing either deadline has serious and often irreversible consequences for enforcing a patent in Canada.

Conclusion: Enforcing a Patent in Canada Requires Timely, Strategic Action

The question of how can a patent be enforced in Canada in 2026 demands more than knowledge of the Patent Act, it requires a strategic assessment that accounts for the PTA regime, the evolving subject-matter landscape under CIPO’s March 2026 Practice Notice, and the specialized PM(NOC) framework for pharmaceuticals. Patentees who move quickly to preserve evidence, assess their PTA-adjusted enforcement window, and select the right procedural forum position themselves for the strongest possible outcome. Those facing infringement claims benefit equally from early and rigorous analysis of invalidity defences and claim-construction arguments. For tailored guidance on patent infringement Canada matters, consulting a specialist IP litigator through the Global Law Experts lawyer directory is a recommended next step.

Sources

1. Canadian Intellectual Property Office, March 2026 Practice Notice on Patentable Subject-Matter
2. Patent Act (Justice Laws of Canada)
3. Health Canada, Guidance on Patented Medicines (Notice of Compliance) Regulations
4. McMillan LLP, Patent Term Adjustments in Canada Are Here
5. Riches, McKenzie & Herbert LLP, Canadian Patent Term Adjustment
6. Heer Law, PM(NOC) Litigation
7. Competition Bureau Canada, Intellectual Property Enforcement Guidelines